Hancock Jaffe Laboratories (NASDAQ:HJLI) and T2 Biosystems (NASDAQ:TTOO) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their risk, earnings, analyst recommendations, dividends, profitability, institutional ownership and valuation.
Insider & Institutional Ownership
1.3% of Hancock Jaffe Laboratories shares are owned by institutional investors. Comparatively, 23.4% of T2 Biosystems shares are owned by institutional investors. 6.4% of Hancock Jaffe Laboratories shares are owned by company insiders. Comparatively, 30.3% of T2 Biosystems shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Volatility and Risk
Hancock Jaffe Laboratories has a beta of 0.53, indicating that its stock price is 47% less volatile than the S&P 500. Comparatively, T2 Biosystems has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500.
This table compares Hancock Jaffe Laboratories and T2 Biosystems’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Hancock Jaffe Laboratories||N/A||-263.14%||-139.10%|
This is a breakdown of recent ratings and recommmendations for Hancock Jaffe Laboratories and T2 Biosystems, as reported by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Hancock Jaffe Laboratories||0||0||1||0||3.00|
Hancock Jaffe Laboratories currently has a consensus target price of $3.00, indicating a potential upside of 1,011.11%. T2 Biosystems has a consensus target price of $5.73, indicating a potential upside of 755.72%. Given Hancock Jaffe Laboratories’ stronger consensus rating and higher possible upside, equities analysts plainly believe Hancock Jaffe Laboratories is more favorable than T2 Biosystems.
Earnings and Valuation
This table compares Hancock Jaffe Laboratories and T2 Biosystems’ top-line revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Hancock Jaffe Laboratories||$30,000.00||173.09||-$7.63 million||N/A||N/A|
|T2 Biosystems||$8.34 million||3.75||-$59.01 million||($1.30)||-0.52|
Hancock Jaffe Laboratories has higher earnings, but lower revenue than T2 Biosystems.
Hancock Jaffe Laboratories beats T2 Biosystems on 7 of the 12 factors compared between the two stocks.
About Hancock Jaffe Laboratories
Hancock Jaffe Laboratories, Inc., a development stage medical device company, develops and sells biological tissue solutions to treat patients with coronary, vascular, end stage renal, and peripheral arterial diseases in the United States and Europe. The company develops and manufactures implantable cardiovascular bioprosthetic devices for patients with cardiovascular disease, peripheral arterial and venous disease, and end stage renal disease. Its products include the Bioprosthetic Heart Valve, a bio-prosthetic heart valve designed to mimic and function like a native heart valve; the CoreoGraft, a device for use as an alternate or supplemental coronary vascular conduit in coronary bypass surgery; and the Venous Valve, a bioprosthetic, pig venous valve for patients with lower limb chronic venous insufficiency. The company was founded in 1987 and is headquartered in Irvine, California. As of July 18, 2006, Hancock Jaffe Laboratories, Inc. is a subsidiary of Leman Cardiovascular SA.
About T2 Biosystems
T2 Biosystems, Inc., an in vitro diagnostics company, develops diagnostic products and product candidates in the United States and internationally. It provides T2 Magnetic Resonance platform that enables detection of pathogens, biomarkers, and other abnormalities in various unpurified patient sample types, including whole blood, plasma, serum, saliva, sputum, and urine. The company also offers T2Dx, a bench-top instrument for detecting pathogens associated with sepsis and Lyme disease, and other applications, as well as T2Candida panel that identifies the species of Candida, a fungal pathogen known to cause sepsis directly from whole blood. In addition, it is developing Candida Auris, a multi-drug resistant pathogen; T2Bacteria, a multiplex diagnostic panel that detects various bacterial pathogens associated with sepsis; and T2Lyme for the detection of various strains of Lyme disease-causing bacteria. The company has collaboration agreements with Canon U.S. Life Sciences, Inc. to develop a diagnostic test panel to detect Lyme disease; and Allergan Sales, LLC to develop detection diagnostic test panel that adds one additional bacteria species to the existing T2Bacteria product candidate, as well as for testing drug resistance directly in whole blood. T2 Biosystems, Inc. was founded in 2006 and is headquartered in Lexington, Massachusetts.
Receive News & Ratings for Hancock Jaffe Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hancock Jaffe Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.